IP Library › Granted Patent US 10,653,687
Granted Patent B2
US 10,653,687 · App. 15/777,495 · Granted May 19, 2020

Methods and pharmaceutical compostions for treating rhabdomyolysis

Inventors: Pascale De Lonlay-Debeney (Paris, FR); Corinne Lebreton (Paris, FR); Yamina Hamel (Paris, FR); Francois-Xavier Mauvais (Paris, FR); Peter Van Endert (Paris, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE; FONDATION IMAGINE; UNIVERSITÉ PARIS DESCARTES ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP); ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
A61K31/4706A61K31/365A61K31/4178A61K31/4745A61K31/517A61K31/5377A61K31/7048A61K31/711A61K31/713A61K45/06A61P21/00A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,687
App. No.
15/777,495
Granted
May 19, 2020
Kind
B2
Abstract

The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis.

Claims (7)

1. A method for treating rhabdomyolysis in a subject in need thereof, comprising the step of administering to said subject a at least one compound selected from the group consisting of one or more TLR9 antagonists and one or more inhibitors of TLR9 expression.

2. The method according to claim 1 , wherein said one or more TLR9 antagonists is a small organic molecule, an oligonucleotide, a polypeptide, an aptamer, or an intra-antibody.

3. The method according to claim 2 , wherein said small organic molecule is selected from the group consisting of chloroquine, primaquine, imidazoquinolines, 4-Amino-quinolines, quinazolines, CMZ 203-84, CMZ 203-85, CMZ 203-88, CMZ 203-88-1, CMZ 203-89, CMZ 203-91, hydroxychloroquine, quinacrine, bafilomycin A, and CPG52364.

4. The method according to claim 2 , wherein said oligonucleotide is CpG ODNi.

5. The method according to claim 1 , wherein the one or more TLR9 antagonists and the one or more inhibitors of TLR9 expression are administered in combination with one or more anti-rhabdomyolysis compounds.

6. The method according to claim 5 wherein said one or more anti-rhabdomyolysis compounds is a compound inhibiting calcium influx.

7. The method of claim 6 , wherein the compound inhibiting calcium influx is dantrium.

Assignments (3)
CHANGE OF NAME Recorded May 12, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059988/0388 →
MERGER Recorded May 12, 2022
From: UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 060044/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2020
From: DE LONLAY-DEBENEY, PASCALE; LEBRETON, CORINNE; HAMEL, YAMINA; MAUVAIS, FRANCOIS-XAVIER; VAN ENDERT, PETER
To: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); FONDATION IMAGINE; UNIVERSITÉ PARIS DESCARTES; ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Reel/Frame 051651/0198 →
Priority Claims (1)
EP 15306831 · Nov 18, 2015 · regional
Continuity (1)
Related Publication 20180325890A1 · Nov 15, 2018